Test Price
2,800 AED✅ Home Collection Available
VIPAS39 Gene Genetic Test for Arthrogryposis, Renal Dysfunction, and Cholestasis Type 2 in UAE | AED 2800 | DHA Approved
Executive Summary & Core Metrics
Comprehensive NGS analysis of the VIPAS39 gene, associated with Arthrogryposis-Renal Dysfunction-Cholestasis (ARCS) type 2, provides definitive diagnosis with 99.9% analytical sensitivity. Conducted under ISO 9001:2015 certified protocols, our service offers hospital-grade home collection, cold-chain transport, and expert post-test genetic counselling to guide clinical management.
✅ Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO Accredited Processing
✅ Premium Logistics
ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy
✅ Clinical Guidance
Telephonic Post-Test Clinical Guidance in result interpretation
✅ Insurance
Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This test uses Next Generation Sequencing to detect pathogenic variants in the VIPAS39 gene causing ARCS type 2, a rare multi-system disorder. The analysis covers all coding exons, flanking intronic regions, and deep intronic variants, ensuring high diagnostic yield for both known and novel mutations.
| Parameter | Our VIPAS39 NGS Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Method | Next Generation Sequencing (NGS) | Sanger Sequencing |
| Coverage | Full gene, deep intronic & flanking regions | Coding exons only |
| Turnaround Time | 3 – 4 weeks | 4 – 6 weeks |
| Analytical Sensitivity | ≥ 99.9% | ~ 95% |
| Clinical Utility | Comprehensive diagnosis, familial variant screening, research‑grade | Targeted detection of known familial mutations only |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that a positive VIPAS39 result must be interpreted alongside clinical findings and family history; a negative result does not exclude the possibility of other genetic etiologies. This test is a powerful tool for diagnosis, but it is not a substitute for comprehensive clinical evaluation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Safety
⚠️ Do not discontinue prescribed medication without consulting your doctor. Genetic testing results require careful integration with ongoing medical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Recent allogeneic blood transfusion (within 4 weeks) or bone marrow transplant can cause mixed chimerism, altering DNA analysis. If applicable, please use an alternative DNA source (buccal swab) or delay testing.
- Emergency Red Flags: If you experience jaundice with confusion (hepatic encephalopathy), severe hypertension, acute kidney injury, or uncontrolled bleeding, seek immediate emergency medical care. This elective genetic test is not intended for acute diagnostic crises.
Patient FAQ & Clinical Guidance
1. What is the purpose of VIPAS39 gene testing?
The VIPAS39 NGS test diagnoses arthrogryposis-renal dysfunction-cholestasis syndrome type 2 by identifying mutations in the VIPAS39 gene. It confirms the diagnosis and guides management of complications, including cholestasis and renal impairment.
2. How is the sample collected and what is the turnaround time?
A standard blood draw is collected at your home by our DHA-licensed phlebotomist under strict cold-chain conditions. Results are reported within 3 to 4 weeks. In cases where blood is contraindicated, a buccal swab may be used after clinical evaluation.
3. Is genetic counselling included?
Yes, pre-test and post-test genetic counselling sessions are provided to explain results and implications for family members. Our genetics team supports you throughout the diagnostic journey.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory certified under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | VIPAS39 Gene Genetic Test (Arthrogryposis, Renal Dysfunction, Cholestasis Type 2) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Peripheral whole blood; buccal swab as alternative subject to clinical evaluation |
| Methodology Used | Next Generation Sequencing (NGS) |
| ICD-10-CM Code | Q87.8 (Other specified congenital malformation syndromes) |
| LOINC Code | 94041-0 (VIPAS39 gene mutation analysis in blood) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians